Patents matching “targeted”

US 12427148

Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

The Regents of the University of California · Granted Sep 30, 2025 · Expires Sep 25, 2045

US 12421315

CLL-1 targeted immunotherapies

REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

US 12410259

CD47 targeted therapies for the treatment of infectious disease

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 9, 2025 · Expires Sep 4, 2045

US 12398193

Targeted replacement of endogenous T cell receptors

The Regents of the University of California · Granted Aug 26, 2025 · Expires Aug 21, 2045

US 12359220

Guided magnetic nanostructures for targeted and high-throughput intracellular delivery

The Regents of the University of California · Granted Jul 15, 2025 · Expires Jul 10, 2045

US 12325755

Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

The Regents of the University of California · Granted Jun 10, 2025 · Expires Jun 5, 2045

US 12303602

Compositions, methods and uses for thermally stable multi-targeted antigens

The Regents of the University of Colorado, a Body Corporate · Granted May 20, 2025 · Expires May 15, 2045

US 12290505

Tissue factor-targeted antibody-drug conjugate

SHANGHAI MIRACOGEN INC. · Granted May 6, 2025 · Expires May 1, 2045

US 12264187

Compositions and methods for targeted therapeutic delivery to bone

Theradaptive, Inc. · Granted Apr 1, 2025 · Expires Mar 27, 2045

US 12257247

Targeted degradation of VAV1

Monte Rosa Therapeutics AG · Granted Mar 25, 2025 · Expires Mar 20, 2045

US 12234461

Targeted non-viral DNA insertions

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION · Granted Feb 25, 2025 · Expires Feb 20, 2045

US 12221607

Multi-targeted single entity conjugates

Alnylam Pharmaceuticals, Inc. · Granted Feb 11, 2025 · Expires Feb 6, 2045

US 12215162

BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

The Board of Regents of the University of Texas System · Granted Feb 4, 2025 · Expires Jan 30, 2045

US 12209256

System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jan 28, 2025 · Expires Jan 23, 2045

US 12209142

SARS-CoV-2 epitope-targeted peptide immunostimulants

The United States of America as represented by the Secretary of the Army · Granted Jan 28, 2025 · Expires Jan 23, 2045

US 12195558

Targeted delivery system and methods of use therefor

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jan 14, 2025 · Expires Jan 9, 2045

US 12157735

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. · Granted Dec 3, 2024 · Expires Nov 28, 2044

US 12134610

Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

CRINETICS PHARMACEUTICALS, INC. · Granted Nov 5, 2024 · Expires Oct 31, 2044

US 12084497

SIRP1α targeted chimeric proteins and uses thereof

Orionis Biosciences, Inc · Granted Sep 10, 2024 · Expires Sep 5, 2044

US 12049464

Compounds for targeted degradation of BRD9

C4 THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

US 12043833

Targeted compositions

ARBUTUS BIOPHARMA CORPORATION · Granted Jul 23, 2024 · Expires Jul 18, 2044

US 12031133

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. · Granted Jul 9, 2024 · Expires Jul 4, 2044

US 11998635

Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites

Northwestern University · Granted Jun 4, 2024 · Expires May 30, 2044

US 11964024

B7H4-targeted antibody-drug conjugates and methods of use thereof

Mersana Therapeutics, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044